Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
2.
Osteoporos Int ; 28(3): 991-999, 2017 03.
Article in English | MEDLINE | ID: mdl-27858122

ABSTRACT

It has been proposed that bisphosphonates cause osteonecrosis of the jaws through impairment of the monocyte population function and proliferation. Such changes have been confirmed in jaw tissues, ex vivo. In this clinical study, we report for the first time a similar pattern of changes in peripheral blood monocytes. INTRODUCTION: The aim of this study is to examine the effect of zolendronic acid administration in the peripheral blood white cell population, seeking a plausible pathophysiological link between bisphosphonates and osteonecrosis of the jaw. METHODS: Twenty-four breast cancer patients, under zolendronic acid treatment for bone metastasis, were included. Peripheral blood samples were obtained prior to and 48 h following zolendronic acid administration. Flow cytometry gated at leukocyte, monocyte, and the granulocyte populations for the CD4/CD8/CD3, CD3/CD16+56/CD45/CD19, CD14/CD123, and CD14/23 stainings were performed. RESULTS: We were able to record a number of changes in the white cell populations after 48 h of zolendronic acid administration. Most importantly, in the monocyte populations, we were able to detect statistically significant increased populations of CD14+/CD23+ (p = 0.038), CD14+/CD23- (p = 0.028), CD14+/CD123+ (p = 0.070, trend), and CD14+/CD123- (p = 0.043). In contrast, statistically significant decreased populations of CD14-/CD23+ (p = 0.037) and CD14-/CD123+ (p = 0.003) were detected. CONCLUSIONS: Our results provide evidence supporting the hypothesis that bisphosphonate administration modifies the monocyte-mediated immune response. An increase of CD14+ peripheral blood monocyte (PBMC) populations along with a decrease of CD14- PBMC populations has been recorded. The latter finding is in accordance with limited-currently existing-evidence and warrants further elucidation.


Subject(s)
Bone Density Conservation Agents/pharmacology , Bone Neoplasms/secondary , Breast Neoplasms/immunology , Diphosphonates/pharmacology , Imidazoles/pharmacology , Lipopolysaccharide Receptors/blood , Monocytes/drug effects , Adult , Aged , Aged, 80 and over , Bone Neoplasms/drug therapy , Bone Neoplasms/immunology , Cell Separation/methods , Female , Flow Cytometry , Follow-Up Studies , Humans , Immunophenotyping , Leukocytes/drug effects , Leukocytes/immunology , Middle Aged , Monocytes/immunology , Prospective Studies , Zoledronic Acid
3.
Mult Scler Relat Disord ; 9: 68-72, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27645348

ABSTRACT

BACKGROUND: Cognitive impairment is experienced by about 50% of patients with Multiple Sclerosis (MS) worldwide and affects their employment, disease management and quality of life in general. The Brief International Cognitive assessment for MS (BICAMS) is a brief, practical and potentially universal battery for cognitive impairment in MS patients. It consists of three tests: the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-2 (CVLT-2) and the Brief Visuospatial Memory Test-Revised (BVMT-R). OBJECTIVE: The objective of this study was to validate the BICAMS in Greek MS patients and controls. METHODS: Forty four MS patients and seventy nine healthy control (HC) participants were recruited and tested. They were group matched for age, education, gender and also premorbid cognitive reserve. All of them completed the three tests of the BICAMS battery. Instead of CVLT-2, the Greek validated form (Greek Verbal Learning Test, GVLT), was used. In addition, cognitive reserve was assessed using the Cognitive Reserve Index questionnaire (CRIq) standardized for the Greek population. RESULTS: Significant difference was found in the performance of the two groups in all tests (p<0.0001, p<0.02, p<0.009 for SDMT, GVLT and BVMT-R respectively). Test-retest reliability was good for all the tests. Based on the criterion of 1 or more tests below the 5th percentile of healthy controls performance, 47% of patients were found impaired. CONCLUSIONS: The study provides validation of BICAMS in Greek population and therefore facilitates the use of this battery in clinical practice and in future studies of MS patients in Greece.


Subject(s)
Cognition Disorders/diagnosis , Cognition , Multiple Sclerosis/diagnosis , Multiple Sclerosis/psychology , Neuropsychological Tests , Adult , Cognition Disorders/complications , Cognition Disorders/epidemiology , Female , Greece , Humans , Male , Middle Aged , Multiple Sclerosis/complications , Multiple Sclerosis/epidemiology , Prevalence , Young Adult
4.
Mol Psychiatry ; 21(10): 1467-76, 2016 10.
Article in English | MEDLINE | ID: mdl-26782054

ABSTRACT

Activity-dependent neuroprotective protein (ADNP), essential for brain formation, is a frequent autism spectrum disorder (ASD)-mutated gene. ADNP associates with microtubule end-binding proteins (EBs) through its SxIP motif, to regulate dendritic spine formation and brain plasticity. Here, we reveal SKIP, a novel four-amino-acid peptide representing an EB-binding site, as a replacement therapy in an outbred Adnp-deficient mouse model. We discovered, for the first time, axonal transport deficits in Adnp(+/-) mice (measured by manganese-enhanced magnetic resonance imaging), with significant male-female differences. RNA sequencing evaluations showed major age, sex and genotype differences. Function enrichment and focus on major gene expression changes further implicated channel/transporter function and the cytoskeleton. In particular, a significant maturation change (1 month-five months) was observed in beta1 tubulin (Tubb1) mRNA, only in Adnp(+/+) males, and sex-dependent increase in calcium channel mRNA (Cacna1e) in Adnp(+/+) males compared with females. At the protein level, the Adnp(+/-) mice exhibited impaired hippocampal expression of the calcium channel (voltage-dependent calcium channel, Cacnb1) as well as other key ASD-linked genes including the serotonin transporter (Slc6a4), and the autophagy regulator, BECN1 (Beclin1), in a sex-dependent manner. Intranasal SKIP treatment normalized social memory in 8- to 9-month-old Adnp(+/-)-treated mice to placebo-control levels, while protecting axonal transport and ameliorating changes in ASD-like gene expression. The control, all d-amino analog D-SKIP, did not mimic SKIP activity. SKIP presents a novel prototype for potential ASD drug development, a prevalent unmet medical need.


Subject(s)
Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Microtubules/physiology , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Amino Acid Motifs , Animals , Autism Spectrum Disorder/etiology , Autism Spectrum Disorder/genetics , Axonal Transport/genetics , Axonal Transport/physiology , Brain/metabolism , Calcium Channels/metabolism , Calcium Channels, R-Type/genetics , Calcium Channels, R-Type/metabolism , Cation Transport Proteins/genetics , Cation Transport Proteins/metabolism , Dendritic Spines/metabolism , Female , Hippocampus/metabolism , Male , Memory , Mice , Microtubules/metabolism , RNA, Messenger/metabolism , Sex Factors , Tubulin/metabolism , Tubulin Modulators/metabolism
5.
Acta Neurol Scand ; 131(5): 305-12, 2015 May.
Article in English | MEDLINE | ID: mdl-25565254

ABSTRACT

OBJECTIVE: The aim of the study was to investigate the expression of different immunological mediators in blood and CSF in patients with acute ON and to estimate whether they were implicated in pro- or anti-inflammatory or even regulatory reactions in comparison with a healthy control group (HC). METHODS: Sixty-four patients between 18 and 59 years of age suffering by acute ON, onset of <4 weeks, were included in the study. Visual tests and brain magnetic resonance imaging (MRI) were performed in ON. Blood and CSF samples were collected from untreated patients and from a gender- and age-matched voluntary HC (n = 32). The mRNA expression of distinct cytokines and neurotrophic factors was assessed by semi/quantitative real-time PCR (RT-PCR). RESULTS: Brain- and glial cell-derived neurotrophic factor (BDNF and GDNF) and interleukin 10 (IL-10) expression was significantly increased in the CSF compared to the blood in both ON and HC (P < 0.001). In the CSF increased levels of BDNF and GDNF of the ON group were positively correlated with the presence of oligoclonal bands (OB). Additionally, patients with gadolinium (gd+) lesions on brain MRI showed increased levels of IL-5 in blood (P = 0.03). CONCLUSION: Our data indicate that both immuno-regulatory and neuroprotective mechanisms may potentially take place relatively early in the course of the ON. The presence of neurotrophic factors in healthy CSF and their overexpression already during the acute phase of ON supports the alertness of CNS defence mechanisms ready to be activated during degenerative events, such as destruction of the myelin.


Subject(s)
Interleukin-10/biosynthesis , Nerve Growth Factors/biosynthesis , Optic Neuritis/immunology , Adolescent , Adult , Female , Humans , Inflammation Mediators/metabolism , Interleukin-10/immunology , Magnetic Resonance Imaging , Male , Middle Aged , Oligoclonal Bands/biosynthesis , Optic Neuritis/blood , Optic Neuritis/cerebrospinal fluid , Real-Time Polymerase Chain Reaction , Young Adult
6.
Brain Inj ; 28(3): 364-9, 2014.
Article in English | MEDLINE | ID: mdl-24377428

ABSTRACT

OBJECTIVE: Xenon and nitrous oxide have been shown to be neuroprotective in vivo and in vitro, but mainly in models of focal cerebral ischaemia. This study aimed to investigate whether the two gases are able to attenuate cerebral injury after global cerebral ischaemia. METHODS: Adult male Wistar rats underwent bilateral common carotid artery occlusion and were ventilated for 1 hour with 21% O2/78% N2. They were then randomized to three groups which continued to receive atmospheric air, 50% N2O/50% O2 and 50% Xe/50% O2 for an additional period of 45 minutes. The number of ischaemic neurons, the cortical volume loss and the immunochemical and molecular expression of c-fos and MMP-9 were evaluated. RESULTS: Xenon reduced the number of ischaemic neurons in the cortex and CA1 hippocampal region (p < 0.001) and decreased the cortical volume loss (p < 0.01). Immunochemical induction of c-fos in the cortex was significantly suppressed (p < 0.01) after administration of xenon. The molecular analysis revealed significant effects of N2O and xenon administration on c-fos and MMP-9 expression. CONCLUSIONS: The data indicate that N2O and xenon administration is neuroprotective 1 hour after bilateral common carotid artery occlusion. These findings provide valuable evidence on the beneficial role of N2O and xenon in global cerebral injury.


Subject(s)
Brain Injuries/pathology , Brain Ischemia/pathology , Neuroprotective Agents/pharmacology , Nitric Oxide/pharmacology , Xenon/pharmacology , Animals , Brain Injuries/drug therapy , Brain Ischemia/drug therapy , Disease Models, Animal , Drug Administration Schedule , Immunohistochemistry , Male , Neuroprotective Agents/administration & dosage , Nitric Oxide/administration & dosage , Random Allocation , Rats , Rats, Wistar , Time Factors , Xenon/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...